<DOC>
	<DOCNO>NCT01491763</DOCNO>
	<brief_summary>20-25 % patient 15 year acute lymphoblastic leukemia ( ALL ) Philadelphia chromosome BCR-ABL rearrangement . Traditionally , intensive chemotherapy follow hematopoietic stem cell transplantation ( HSCT ) form basis allogeneic treatment disease , result poor ( 60-75 % complete remissions-RC-and probability long-term survival le 20 % ) . The effectiveness imatinib hematologic response patient Ph + ( observed phase I II ) lead use phase III trial combination chemotherapy . They saw chance obtain RC 90 % , acceptable toxicity , molecular response rate ( MR ) 40-50 % , prolong follow-up study , probability disease-free survival ( DFS ) 30-50 % , significantly high historical control chemotherapy without imatinib . This lead approval imatinib rating agency U.S. , Europe Japan treatment Ph + combination chemotherapy . Of study lead approval indication imatinib , incur , follow conclusion draw : There specific pattern combination imatinib ( dose 600 mg / day , po ) chemotherapy . However , compare concomitant alternate first achieve high rate RM end induction , although influence DFS . In study elderly patient achieve high CR rate ( almost 100 % series ) , imatinib glucocorticoid , suggest attenuate induction may sufficient achieve CR young patient minimal toxicity , compromise administration treatment allow allogeneic HSCT minimal toxic load possible . Although consensus indication allogeneic HSCT first CR give imatinib associate intensive chemotherapy option do study . The allogeneic HSCT effective carry complete molecular response great residual disease . However , impact MRI obtain early ( induction ) survival clear . So far-reaching goal make TPH complete molecular response situation great . The relapse disease molecular level still short-term ( less 3 month ) hematological relapse . This implies need frequent monitor residual disease ( ER ) The frequency relapse post HSCT high ( around 30 % ) , raise need post HSCT treatment , include imatinib include . Are currently ongoing clinical trial compare systematic administration imatinib administration TPH face detect ER . The applicability administration imatinib HSCT limit toxicity related procedure TPH , make frequent dose reduction discontinuation . Therefore , reasonable approximation treatment Ph + outside context clinical trial get many molecular response allogeneic HSCT position make MRI complete great . After TPH , must close monitoring ER , imatinib administer soon notice loss molecular response . In patient make allogeneic HSCT lack histocompatible donor contraindication realization recommend imatinib chemotherapy , although study undergo autologous HSCT , follow treatment `` maintenance '' imatinib . The low toxicity autologous HSCT effect graft versus leukemia strongly recommend administration maintenance therapy imatinib combine chemotherapy .</brief_summary>
	<brief_title>Chemotherapy Imatinib Young Adults With Acute Lymphoblastic Leukemia Ph ( BCR-ABL ) POSITIVE</brief_title>
	<detailed_description>Induction Chemotherapy - Vincristine ( VCR ) : 1.5 mg/m2 ( maximum dose 2 mg ) iv day 1 , 8 , 15 22 - daunorubicin ( DNR ) 45 mg/m2 i.v . day 1 , 8 , 15 22 - Prednisone ( PDN ) : 60 mg/m2 per day , i.v . p.o. , day 1-27 - Imatinib 600 mg p.o . day 1 begin consolidation . Important Note : The administration imatinib initiate soon outcome cytogenetic molecular study , know normal condition prophase consolidation Patients RC shall minimum 2 week find . Patients discontinue treatment imatinib period . Minimum count start consolidation : neutrophil &gt; 1x109 / L platelet &gt; 100x109 / L. - Mercaptopurine ( MP ) 50 mg/m2 , p.o . day 1 7 , 28 35 56 63 - MTX : 1.5 g/m2 , i.v . continuous infusion 24 hour day 1 , 28 56 . - VP-16 : 100 mg/m2 every 12 hour , i.v . ( 1 hour infusion ) day 14 42 - ARA-C : 1000 mg/m2 every 12 hour , i.v . ( 3-hour infusion ) day 14-15 42-43 - triple intrathecal treatment day 1 , 28 56 - Imatinib 600 mg / po , day 1 15 day TPH . During consolidation therapy recommend primary prophylaxis G-CSF find neutropenia ( &lt; 0.5 x109 / L ) . This factor administer daily neutrophil count &gt; 1x109 / L two consecutive measurement . Alternatively , PEG-filgrastim use ( eg 16 44 ) , discretion center Allogenic THP Autologous TPH</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients Ph ( BCR/ABL ) positive de novo &lt; 55 year old ( advisable include patient 55 year LAL07OPH protocol ) . Performance status 02 ( Appendix B ) may include patient performance status &gt; 2 attributable LAL . Patients without functional impairment organ : liver function : total bilirubin , AST , ALT , alfaGT alkaline phosphatase less 3 time upper limit normal laboratory renal function : serum creatinine &lt; 2 mg/dL clearance creatinine &gt; 30 ml/min ( except renal function attributable LAL ) cardiac function ( Appendix B ) normal : ventricular EF &gt; 50 % , absence severe chronic respiratory disease . In event alteration secondary disease discretion investigator determine patient include trial . Any variety LAL Patients history coronary artery disease , valvular hypertensive heart disease Patients chronic liver disease Patients chronic respiratory failure Renal failure due LAL Patients positive HIV status No serious neurological abnormality due LAL Impact overall severe ( grade 3 4 WHO scale ) attributable LAL Pregnant breastfeed initial blast crisis CML</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>